MedTrace Logo

A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

NCT04202159 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 187

Last updated 2023-08-03

No results posted yet for this study

Summary

The primary purpose of this study is to investigate the effectiveness reflected by the retention rate of perampanel as the only add-on treatment in adult participants with primary generalized tonic-clonic (PGTC) or secondarily generalized tonic-clonic (SGTC) seizures based on focal or idiopathic generalized epilepsy in a non-interventional (observational) setting.

Conditions

Interventions

DRUG

Perampanel

Perampanel tablets.

DRUG

Perampanel

Perampanel oral suspension.

Sponsors & Collaborators

  • Eisai GmbH

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-21
Primary Completion
2023-03-31
Completion
2023-03-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04202159 on ClinicalTrials.gov